DEGARELIX
| Title | Journal |
|---|---|
| Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses. | Clinical chemistry and laboratory medicine 20121101 |
| Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. | International journal of urology : official journal of the Japanese Urological Association 20120701 |
| The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients. | Urology 20120701 |
| Editorial comment. | Urology 20120701 |
| [The efficacy of degarelix on LUTS (Lower urinary tract symptoms) relief in patients with prostate cancer]. | Urologia 20120701 |
| The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer. | Japanese journal of clinical oncology 20120601 |
| Androgen deprivation therapy: past, present and future. | BJU international 20120601 |
| Short-term testosterone manipulations modulate visual recognition memory and some aspects of emotional reactivity in male rhesus monkeys. | Physiology & behavior 20120515 |
| Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer. | BJU international 20120401 |
| Follicular and endocrine profiles associated with different GnRH-antagonist regimens: a randomized controlled trial. | Reproductive biomedicine online 20120201 |
| Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. | The Journal of urology 20111101 |
| In vitro studies investigating the interactions between degarelix, a decapeptide gonadotropin-releasing hormone blocker, and cytochrome P450. | Basic & clinical pharmacology & toxicology 20110901 |
| A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. | The Journal of urology 20110901 |
| Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide. | Prostate cancer and prostatic diseases 20110601 |
| Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer. | International journal of clinical practice 20110501 |
| Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer. | Anti-cancer drugs 20110301 |
| Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. | The Journal of urology 20101201 |
| Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples. | British journal of clinical pharmacology 20101001 |
| Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. | BJU international 20100701 |
| Degarelix. More rapid medical castration, nothing more. | Prescrire international 20100601 |
| Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. | European urology 20100501 |
| New Drugs2010, PART 1. | Nursing 20100201 |
| Evaluation of degarelix in the management of prostate cancer. | Cancer management and research 20100101 |
| Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer. | Expert review of anticancer therapy 20091201 |
| Degarelix (firmagon) for prostate cancer. | The Medical letter on drugs and therapeutics 20091019 |
| Degarelix. | Drugs 20091001 |
| Degarelix acetate for the treatment of prostate cancer. | Drugs of today (Barcelona, Spain : 1998) 20091001 |
| Degarelix for prostate cancer. | Expert opinion on investigational drugs 20090601 |
| [GnRH antagonists--a new therapy option for advanced prostate cancer]. | Aktuelle Urologie 20090501 |
| Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer. | Future oncology (London, England) 20090501 |
| Twenty-five year evolution of medical hormonal therapy for prostate cancer. | BJU international 20090101 |
| Degarelix and its therapeutic potential in the treatment of prostate cancer. | Clinical interventions in aging 20090101 |
| Degarelix: a new approach for the treatment of prostate cancer. | Neuroendocrinology 20090101 |
| Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer. | Clinical therapeutics 20090101 |
| The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. | BJU international 20081201 |
| A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. | The Journal of urology 20081101 |
| Management of advanced prostate cancer: gonadotropin-releasing hormone blockers might improve prognosis. | European urology 20081001 |
| Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. | European urology 20081001 |
| Management of advanced prostate cancer: can we improve on androgen deprivation therapy? | BJU international 20080601 |
| Testosterone surge: rationale for gonadotropin-releasing hormone blockers? | Urology 20080601 |
| A new model of patient tumor-derived breast cancer xenografts for preclinical assays. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070701 |
| Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues. | British journal of clinical pharmacology 20070601 |
| Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist. | The Journal of pharmacology and experimental therapeutics 20070301 |
| Semi-mechanistic pharmacodynamic modeling for degarelix, a novel gonadotropin releasing hormone (GnRH) blocker. | Journal of pharmacokinetics and pharmacodynamics 20061001 |
| Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. | Journal of medicinal chemistry 20060615 |
| Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II. | Journal of medicinal chemistry 20050728 |
| Synthesis and biological activity of GnRH antagonists modified at position 3 with 3-(2-methoxy-5-pyridyl)-alanine. | The journal of peptide research : official journal of the American Peptide Society 20050201 |
| Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. | The Journal of pharmacology and experimental therapeutics 20020401 |
| GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6. | Journal of medicinal chemistry 20010201 |